The GP2 peptide: A HER2/neu-based breast cancer vaccine

Preclinical studies suggest that GP2, a HER2/neu‐derived peptide, is immunogenic. Subsequent phase I clinical trials demonstrated that GP2‐based vaccines are safe and effective in stimulating peptide‐specific immunity. A GP2 peptide vaccine is currently being evaluated in a phase II efficacy trial e...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of surgical oncology 2012-04, Vol.105 (5), p.452-458
Hauptverfasser:	Clive, Kevin S., Tyler, Josh A., Clifton, G. Travis, Holmes, Jarrod P., Ponniah, Sathibalan, Peoples, George E., Mittendorf, Elizabeth A.
Format:	Artikel
Sprache:	eng
Schlagworte:	Antibodies, Monoclonal, Humanized - therapeutic use Antineoplastic Agents - therapeutic use Breast Neoplasms - immunology Breast Neoplasms - prevention & control cancer Cancer Vaccines - adverse effects Cancer Vaccines - immunology Clinical Trials as Topic Dimerization Female GP2 GPI-Linked Proteins - adverse effects GPI-Linked Proteins - immunology Granulocyte-Macrophage Colony-Stimulating Factor - therapeutic use HER2/neu HLA-A2 Antigen - immunology Humans Immunoglobulin G - immunology immunotherapy Immunotherapy - methods Mucin-1 - metabolism Peptide Fragments - metabolism Receptor, ErbB-2 - immunology Receptor, ErbB-2 - metabolism Trastuzumab vaccine
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Preclinical studies suggest that GP2, a HER2/neu‐derived peptide, is immunogenic. Subsequent phase I clinical trials demonstrated that GP2‐based vaccines are safe and effective in stimulating peptide‐specific immunity. A GP2 peptide vaccine is currently being evaluated in a phase II efficacy trial enrolling breast cancer patients. This article reviews initial studies characterizing GP2, clinical trials investigating GP2‐based vaccines, and novel immunotherapy strategies incorporating GP2 in combination with other peptides or with the monoclonal antibody trastuzumab. J. Surg. Oncol. 2012; 105:452–458. © 2012 Wiley Periodicals, Inc.
ISSN:	0022-4790 1096-9098
DOI:	10.1002/jso.21723